1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis ErbB / Her Receptor Antagonists

Competitor Analysis ErbB / Her Receptor Antagonists

  • July 2013
  • -
  • La Merie Publishing
  • -
  • 168 pages

Competitor Analysis ErbB / Her Receptor Antagonists

Product description

The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody  therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.
The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis ErbB / Her Receptor Antagonists
Competitor Analysis ErbB / Her Receptor Antagonists
Table of Contents

• Sales of Small Molecules Inhibitors of the ErbB/Her Receptor Family
• Sales of Antibodies Targeting ErbB/Her Receptors

1) Small Molecules Targeting the ErbB/Her Receptor Family

a) Selective EGF-R Tyrosine Kinase (TK) Inhibitors

- Tarceva Pipeline

- Iressa Pipeline

- Pipeline of Other EGF-R Selective TK Inhibitors

b) Selective Her2 (ErbB2) TK Inhibitors

c) Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors

- Tykerb  Pipeline

- Pipeline of Other Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors

d) Pan-Her (EGF-R, Her2 and Her4) / pan-Erb (ErbB1, ErbB2, ErbB4) TK Inhibitors

- Gilotrif Pipeline

- Neratinib Pipeline

- Dacomitinb Pipeline

- Poziotinib Pipeline

- Pipeline of Other Pan-Her Tk Inhibitors

e) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) Inhibition

f) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) and Her2 (ErbB2) Inhibition
2) Biologics (Cells, Proteins, RNA) Targeting the ErbB/Her Receptor Family
3) Vaccines Targeting the ErbB/Her Receptor Family

a) EGF-R (ErbB1) Vaccines

b) Her2 (ErbB2) Vaccines

c) Her3 (ErbB3) Vaccines
4) Antibodies Targeting the ErbB/Her Receptor Family

a) Selective EGF-R (ErbB1) Antibodies

- Erbitux Pipeline

- Vectibix Pipeline

- Nimotuzumab Pipeline

- Pipeline of Other Selective EGF-R (ErbB1) Antibodies

- Biosimilar Cetuximab Pipeline

- Biosimilar Panitumumab Pipeline


b) Selective Her2 (ErbB2) Antibodies

- Herceptin Pipeline

- Perjeta Pipeline

- Kadcyla Pipeline

- Pipeline of Other Selective Her2 (ErbB2) Antibodies

- Biosimilar Trastuzumab Pipeline

c) Selective Her3 (ErbB3) Antibodies

d) Dual and Pan ErbB / Her Antibodies

e) Dual Target Antibodies incl. ErbB/Her Receptor Antagonism
5) Corporate ErbB/Her Receptor Antagonist Randamp;D Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025 Summary Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid ...

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Related Market Segments :

Therapy
Monoclonal Antibody
Lung Cancer

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.